Strasbourg, France, March 30, 2017, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotechnology company focused on designing and developing viral-based immune-targeted therapies for the treatment of cancers and infectious diseases, announces today that it will present a poster with new and encouraging preclinical data of a next generation armed engineered oncolytic virus at the American Association for Cancer Research annual meeting in Washington, DC.
This immunological data further support the development of armed oncolytic viruses that have the capacity to modulate the tumor micro-environment and improve T-cell infiltration in the tumor.
Key highlights:
• The next generation Oncolytic Virus (OV) demonstrated its ability to induce complete response in the primary tumor and immune-mediated regression of distant metastases;
• This Oncolytic Virus induced immunogenic tumor cell death and generated a systemic immune response. This response is associated with an increase of cytotoxic CD8+ T cells infiltration (particularly PD-1+ CD8+ T cells) and a decrease of regulatory T-cells in the tumor;
• The therapeutic activity of this next generation Oncolytic Virus was further enhanced when combined with either chemotherapy or with immune checkpoint inhibitor (ICI) such as anti-PD-1 or anti-CTLA-4.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer